Na żywo · Q4 2026·Sieć handlowa Aktywne pozycje: 24·FX ECB · — —:— CET·Aktualizacja co godzinęportal v3 · —
RynkiCenyAktualnościBlogMetodykaPlatforma B2B
Live · Q4 2026

Rynki UE,
w jednym kanale.

Warstwa informacyjna platformy B2B ViraChem. Aktualne ceny spot, wiadomości R&D z otwartych rejestrów oraz badania terenowe dla laboratoriów farmaceutycznych i biotechnologicznych w całej Europie — prosto z naszej sieci handlowej, odświeżane co godzinę.

Pozycje z ceną
24
Surowy proszek · stawka progu kg
Śr. 7-dniowa Δ
+0.8%▲
W aktywnych pozycjach
FX · ECB
EUR/USD
Dzienny kurs referencyjny
Częstotliwość
1 h
TTL dla każdego wiersza
/ 02 Ceny spot

Ceny na żywo i analiza/ 7-day spot · €/g · 24 compounds

Aktualizowane co godzinęWszystkie związki →
Związek · chemia
Trend 7 dni
€/g · spot
1d · 7d · 30d
Czystość HPLC
BPC-157 acetate structure
BPCBPC-157 acetate· raw powder
In Vivoacetate
CAS137525-51-0MW1419.5 g/molSólacetateCID9941957SEQGEPPPGKPADDAGLVInChIHEEWEZGQMLZMFE-RKGINYAYSA-N
€156/g
1d~+2.6%7d▼ ~-5.5%30d~+11.1%
≥98%
→
GHK-cu acetate structure
GHKGHK-cu acetate· raw powder
In Vivoacetate
CAS89030-95-5MW401.91 g/molSólacetateCID139035031SEQGly-His-Lys (Cu²⁺)InChILREZPQNYQZAPJC-ACMTZBLWSA-L
€4/g
1d~-0.7%7d▼ ~-3.5%30d~-11.2%
≥98%
→
Mots-c acetate structure
MOTMots-c acetate· raw powder
In Vivoacetate
CAS1627580-64-6MW2174.6 g/molSólacetateCID146675088SEQMRWQEMGYIFYPRKLRInChIWYTHCOXVWRKRAH-LOKRTKBUSA-N
€277/g
1d~-1.3%7d▼ ~-4.8%30d~-2.8%
≥98%
→
CJC 1295 NO DAC acetate structure
CJCCJC 1295 NO DAC acetate· raw powder
In Vivoacetate
CAS863288-34-0MW3367.9 g/molSólacetateCID56841945SEQY-(D-A)-D-A-I-F-T-Q-S-Y-R-K-V-L-A-Q-L-S-A-R-K-L-L-Q-D-I-L-S-R-NH2InChIXOZMWINMZMMOBR-HRDSVTNWSA-N
€512/g
1d~+1.6%7d▼ ~-1.4%30d~+14.2%
≥98%
→
Epithalon acetate structure
EPIEpithalon acetate· raw powder
Industrialacetate
CAS64082-79-7MW390.35 g/molSólacetateCID219042SEQAEDGInChIHGHOBRRUMWJWCU-FXQIFTODSA-N
€105/g
1d~+0.5%7d▲ ~+9.3%30d~+3.2%
>90%
→
Thymosin alpha 1 acetate structure
THYThymosin alpha 1 acetate· raw powder
In Vivoacetate
CAS62304-98-7MW3108.3 g/molSólacetateCID16130571SEQSDAAVDTSSEITTKDLKEKKEVVEEAENInChINZVYCXVTEHPMHE-ZSUJOUNUSA-N
€562/g
1d~-2.2%7d▼ ~-5.7%30d~-4.6%
≥98%
→
Thymulin acetate structure
THY3Thymulin acetate· raw powder
Industrialacetate
CAS63958-90-7MW858.9 g/molSólacetateCID71300623SEQXAKSQGGSNInChILIFNDDBLJFPEAN-YTAPOSPOSA-N
€165/g
1d~-0.2%7d▼ ~-4.5%30d~-6.0%
>90%
→
5-Amino 1MQ chloride structure
AMI5-Amino 1MQ chloride· raw powder
In Vivochloride
CAS685079-15-6MW159.21 g/molSólchlorideCID950107InChIZMJBCEIHNOWCMC-UHFFFAOYSA-O
€2/g
1d~+3.3%7d▼ ~-2.4%30d~-9.1%
≥98%
→
AOD-9604 acetate structure
AODAOD-9604 acetate· raw powder
In Vivoacetate
CAS221231-10-3MW1815.1 g/molSólacetateCID71300630SEQYLRIVQCRSVEGSCGFInChIGVIYUKXRXPXMQM-BPXGDYAESA-N
€874/g
1d~-1.6%7d▼ ~-5.4%30d~-9.8%
≥98%
→
DSIP acetate structure
DSIDSIP acetate· raw powder
In Vivoacetate
CAS62568-57-4MW848.8 g/molSólacetateCID68816SEQWAGGDASGEInChIZRZROXNBKJAOKB-GFVHOAGBSA-N
€196/g
1d~+3.7%7d▲ ~+7.9%30d~+10.4%
≥98%
→
Ipamorelin acetate structure
IPAIpamorelin acetate· raw powder
In Vivoacetate
CAS170851-70-4MW711.9 g/molSólacetateCID9831659SEQXHXFKInChINEHWBYHLYZGBNO-BVEPWEIPSA-N
€243/g
1d~-0.9%7d▼ ~-4.8%30d~+5.3%
≥98%
→
KPV
KPVKPV acetate· raw powder
In Vivo
€223/g
1d~+0.1%7d▼ ~-1.7%30d~-7.5%
≥98%
→
Kisspeptin-10 acetate structure
KISKisspeptin-10 acetate· raw powder
In Vivoacetate
CAS374675-21-5MW1302.4 g/molSólacetateCID25240297SEQYNWNSFGLRFInChIRITKWYDZSSQNJI-INXYWQKQSA-N
€285/g
1d~-3.1%7d▼ ~-5.3%30d~-4.3%
≥98%
→
LL-37 acetate structure
LLALL-37 acetate· raw powder
In Vivoacetate
CAS154947-66-7MW4493 g/molSólacetateCID16198951SEQLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESInChIPOIUWJQBRNEFGX-XAMSXPGMSA-N
€774/g
1d~+2.8%7d▲ ~+3.7%30d~+0.3%
≥98%
→
Melanotan 2 acetate structure
MELMelanotan 2 acetate· raw powder
Industrialacetate
CAS121062-08-6MW1024.18 g/molSólacetateCID92432SEQXDHFRWKInChIJDKLPDJLXHXHNV-MFVUMRCOSA-N
€162/g
1d~-3.7%7d▲ ~+5.7%30d~+12.6%
>90%
→
NAD+ structure
NADNAD+· raw powder
In Vivo
CAS53-84-9MW663.4 g/molCID5892InChIBAWFJGJZGIEFAR-NNYOXOHSSA-N
€1/g
1d~+4.7%7d▲ ~+8.5%30d~+8.5%
≥98%
→
PEG
PEGPEG-MGF acetate· raw powder
In Vivoacetate
MW4888 g/molSólacetateSEQYQPPSTNKNTKSQRRKGSTFEERK-NH2
€1,380/g
1d~+1.4%7d▲ ~+11.0%30d~+14.9%
≥98%
→
PT-141 acetate structure
PTAPT-141 acetate· raw powder
In Vivoacetate
CAS189691-06-3MW1025.2 g/molSólacetateCID9941379SEQXDHFRWKInChIFFHBJDQSGDNCIV-MFVUMRCOSA-N
€378/g
1d~0.0%7d▲ ~+6.3%30d~+0.4%
≥98%
→
Retatrutide acetate structure
RETRetatrutide acetate· raw powder
In Vivoacetate
CAS2381089-83-2MW4731.33 g/molSólacetateCID171390338SEQY-Aib-QGTFTSDYSI-αMeLeu-LDK-Lys(19-carboxy-nonadecanoyl-γGlu-AEEA)-AQ-Aib-AFIEYLLEGGPSSGAPPPS-NH₂InChIMLOLQJNKXBNWFW-SAGGEDDASA-N
€164/g
1d~-3.6%7d▼ ~-8.2%30d~-12.4%
≥98%
→
SS-31 acetate structure
SS3SS-31 acetate· raw powder
In Vivoacetate
CAS736992-21-5MW639.8 g/molSólacetateCID11764719SEQRXKFInChISFVLTCAESLKEHH-WKAQUBQDSA-N
€329/g
1d~+2.6%7d▲ ~+11.0%30d~+2.0%
≥98%
→
Selank acetate structure
SELSelank acetate· raw powder
In Vivoacetate
CAS129954-34-3MW751.9 g/molSólacetateCID11765600SEQTKPRPGPInChIJTDTXGMXNXBGBZ-YVHUGQOKSA-N
€187/g
1d~+1.7%7d▼ ~-0.9%30d~-9.1%
≥98%
→
Semax acetate structure
SEMSemax acetate· raw powder
In Vivoacetate
CAS80714-61-0MW813.9 g/molSólacetateCID9811102SEQMEHFPGPInChIAFEHBIGDWIGTEH-AQRCPPRCSA-N
€192/g
1d~+1.4%7d▲ ~+2.9%30d~+9.5%
≥98%
→
Tesamorelin acetate structure
TESTesamorelin acetate· raw powder
In Vivoacetate
CAS218949-48-5MW5136 g/molSólacetateCID16137828SEQYADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARLInChIQBEPNUQJQWDYKU-BMGKTWPMSA-N
€541/g
1d~+1.4%7d▲ ~+5.8%30d~+3.0%
≥98%
→
Thymosin beta-4 acetate structure
THY4Thymosin beta-4 acetate· raw powder
In Vivoacetate
CAS77591-33-4MW4963 g/molSólacetateCID45382195SEQSDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGESInChIUGPMCIBIHRSCBV-UHFFFAOYSA-N
€571/g
1d~+0.6%7d▲ ~+2.3%30d~-2.1%
≥98%
→

Prices derive from ViraChem’s active network of trade, converted to EUR at the ECB daily reference rate for each transaction date. Metodyka →

24 compounds·€/g·ECB · EUR/USD 1.1188·Updated 07:59 CET·Q4 2026
/ 03 Puls wiadomości

Puls wiadomości i najnowsze badania/ otwarte rejestry · blog

Aktualizowane co godzinęPełny kanał →
Kanał wiadomości R&DEUROPE PMC · CT.GOV
13 OCT
PreprintbioRxiv· immunology
Self-reactive human CD8⁺ T cells restricted by HLA-E mediate immunoregulatory and antiviral functions
HLA-E constitutively presents self VL9 peptides on healthy cells, signaling an intact HLA class I pathway and protecting cells from natural killer cell attack. Beyond this canonical role, HLA-E-restricted CD8 T cells …
Walters, L. C.; Guo, X.; Casquero, C.; Urbach, J. M.; Leddy, O.; Cakan, E.; Chan, A. O.; Balivada, P. A.; Wisner, H.; Bryson, B. D.; Whit…
↗
13 OCT
Badanie kliniczneClinicalTrials.gov· PHASE3 · RECRUITING
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer …
Merck Sharp & Dohme LLC
↗
13 OCT
Badanie kliniczneClinicalTrials.gov· PHASE2 · NOT_YET_RECRUITING
Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
This trial proposes to evaluate the immunologic and potential clinical effectiveness of intensive locoregional sequential intraperitoneal (IP) cisplatin (IPC) with intravenous (iv) paclitaxel followed by peritoneal in…
Kalinski, Pawel, MD, PhD
↗
13 OCT
Badanie kliniczneClinicalTrials.gov· PHASE2 · RECRUITING
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the…
National Cancer Institute (NCI)
↗
13 OCT
Badanie kliniczneClinicalTrials.gov· PHASE2 · RECRUITING
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
Patients with with recurrent or progressive medulloblastoma, ependymoma, atypical teratoid rhabdoid tumor (ATRT), and CNS tumors of various histologies have a very poor prognosis whether treated with conventional chem…
Medical University of Vienna
↗
13 OCT
Badanie kliniczneClinicalTrials.gov· PHASE2 · NOT_YET_RECRUITING
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
The purpose of this study is to assess the safety, tolerability, and surgical feasibility of preoperative Pumitamig-based therapy and other molecules in resectable, Early-Stage Non-Small Cell Lung Cancer
Bristol-Myers Squibb
↗
24 compounds·€/g·ECB · EUR/USD 1.1188·Updated 07:59 CET·Q4 2026
24 compounds·€/g·ECB · EUR/USD 1.1188·Updated 07:59 CET·Q4 2026
/ 06 Źródła danych
Europe PMCClinicalTrials.govUSPTObioRxivECB
Otwarte rejestry · odświeżanie dzienne
/ platforma handlowa

Chcesz kupić,
a nie tylko czytać?

Platforma B2B — katalog produktów, narzędzia RFQ, dokumentacja analityczna i wysyłka na terenie UE — znajduje się pod adresem virachemical.com.

Odwiedź virachemical.com
/ czym się zajmujemy

Gotowe formaty, produkcja na zamówienie, napełnianie i konfekcjonowanie.

71 specyfikacji klas w 11 kategoriach — Pharma, Cosmetic, Food, Analytical, IVD, Cell culture, Industrial i inne.

Zobacz usługi
/ zapytanie ofertowe

Zapytania i wyceny progów ilościowych w 1 dzień roboczy.

Podaj związek, skalę i postać. Wracamy z dostępnością, czasem realizacji i kosztem dostawy na terenie UE.

Poproś o wycenę